Immunovant surged after releasing early but “compelling” Phase 2b data for IMVT-1402, its next-generation FcRn inhibitor in difficult-to-treat rheumatoid arthritis (D2T RA). The open-label 16-week findings showed responses across ACR20, ACR50, and ACR70 assessments in patients who had failed TNF and JAK inhibitor therapies. Company commentary pointed to discussions with the FDA as the next step, while the program remains ongoing. The readout arrives as competitors continue refining FcRn strategies to improve outcomes in antibody-mediated autoimmune disease. Separately, Relay reported a strong efficacy signal for zovegalisib (RLY-2608) in a Phase 2 trial of PIK3CA-driven vascular anomalies, with a 60% volumetric response rate described as outperforming expectations. The PI3Kα inhibitor is already in late-stage development across other settings where PI3K signaling is implicated.